Skip to main content

Human Papilloma Virus Infection

1
Pipeline Programs
6
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Guard Therapeutics
Guard TherapeuticsSweden - Stockholm
1 program
1
Recombinant NonavalentPhase 21 trial
Active Trials
NCT05694728Completed780Est. Jan 2021
Biocorp
BiocorpFrance - Issoire
1 program
HPV Diagnostic KitN/A1 trial
Active Trials
NCT06111911Completed900Est. Oct 2022
MSD
MSDIreland - Ballydine
1 program
Post-Licensure Study of the Safety of GARDASIL™ in Males (V501-070)N/A1 trial
Active Trials
NCT01567813Completed114,035Est. Jun 2019
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
Post-Licensure Study of the Safety of GARDASIL™ in Males (V501-070)N/A
Hologic
HologicMARLBOROUGH, MA
1 program
Thinprep® LBCN/A1 trial
Active Trials
NCT02634190Completed10,000Est. Dec 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Guard TherapeuticsRecombinant Nonavalent
BiocorpHPV Diagnostic Kit
MSDPost-Licensure Study of the Safety of GARDASIL™ in Males (V501-070)
HologicThinprep® LBC

Clinical Trials (4)

Total enrollment: 125,715 patients across 4 trials

NCT05694728Guard TherapeuticsRecombinant Nonavalent

A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine

Start: May 2020Est. completion: Jan 2021780 patients
Phase 2Completed
NCT06111911BiocorpHPV Diagnostic Kit

Detection of High-Risk HPV in Urine and Cervical Swab Specimen Using HPV Diagnostic Kit (Bio Farma)

Start: Apr 2022Est. completion: Oct 2022900 patients
N/ACompleted
NCT01567813MSDPost-Licensure Study of the Safety of GARDASIL™ in Males (V501-070)

Post-Licensure Study of the Safety of GARDASIL™ in Males (V501-070)

Start: Jun 2011Est. completion: Jun 2019114,035 patients
N/ACompleted
NCT02634190HologicThinprep® LBC

Clinical Evaluation of the APTIMA® HPV Assay and Comparison With the HR HC2® Test Using LBC ThinPrep® Specimens

Start: Jun 2009Est. completion: Dec 202110,000 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.